Laboratorio Reig Jofre, S.A. (RJF.MC)
EUR 2.73
(-0.36%)
EUR 2.73
(-0.36%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 35.13 Million EUR | 15.44% |
| 2022 | 30.43 Million EUR | 12.9% |
| 2021 | 24.66 Million EUR | 0.89% |
| 2020 | 24.31 Million EUR | 37.98% |
| 2019 | 19.38 Million EUR | 18.14% |
| 2018 | 17.7 Million EUR | 6.09% |
| 2017 | 15.77 Million EUR | 3.53% |
| 2016 | 19.14 Million EUR | -13.05% |
| 2015 | 17.52 Million EUR | 373.71% |
| 2014 | 3.67 Million EUR | 42.14% |
| 2013 | 2.93 Million EUR | 149.41% |
| 2012 | 3.76 Million EUR | -24.85% |
| 2011 | 17.22 Million EUR | 619.08% |
| 2010 | -11.52 Million EUR | 99.09% |
| 2009 | -28.94 Million EUR | -242.88% |
| 2008 | 20.25 Million EUR | 604.28% |
| 2007 | 15.45 Million EUR | -75.36% |
| 2006 | 6.1 Million EUR | 127.04% |
| 2005 | 4.66 Million EUR | -7.82% |
| 2004 | 5.57 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 8.88 Million EUR | -1.77% |
| 2024 Q1 | 10.26 Million EUR | 15.41% |
| 2024 Q2 | 9.8 Million EUR | -4.43% |
| 2023 Q1 | 9.24 Million EUR | 0.01% |
| 2023 Q3 | 7.63 Million EUR | -10.68% |
| 2023 FY | - EUR | 15.44% |
| 2023 Q2 | 8.54 Million EUR | -7.54% |
| 2023 Q4 | 8.89 Million EUR | 16.49% |
| 2022 Q4 | 9.24 Million EUR | 28.39% |
| 2022 FY | - EUR | 12.9% |
| 2022 Q3 | 7.19 Million EUR | 0.0% |
| 2021 Q3 | 6.65 Million EUR | 46.96% |
| 2021 Q2 | 4.52 Million EUR | -48.58% |
| 2021 Q1 | 8.8 Million EUR | 18.03% |
| 2021 FY | - EUR | 0.89% |
| 2021 Q4 | 6.97 Million EUR | 4.82% |
| 2020 Q3 | 6.27 Million EUR | 26.95% |
| 2020 FY | - EUR | 37.98% |
| 2020 Q1 | 8.04 Million EUR | 14.68% |
| 2020 Q2 | 4.94 Million EUR | -38.56% |
| 2020 Q4 | 7.45 Million EUR | 18.89% |
| 2019 Q1 | 5.62 Million EUR | 4.7% |
| 2019 FY | - EUR | 18.14% |
| 2019 Q4 | 7.01 Million EUR | 124.81% |
| 2019 Q3 | 3.12 Million EUR | -14.12% |
| 2019 Q2 | 3.63 Million EUR | -35.39% |
| 2018 FY | - EUR | 6.09% |
| 2018 Q1 | 4.69 Million EUR | -24.8% |
| 2018 Q4 | 5.37 Million EUR | 56.25% |
| 2018 Q3 | 3.43 Million EUR | 19.06% |
| 2018 Q2 | 2.88 Million EUR | -38.52% |
| 2017 FY | - EUR | 3.53% |
| 2017 Q4 | 6.24 Million EUR | 161.27% |
| 2017 Q3 | 2.39 Million EUR | -4.75% |
| 2017 Q2 | 2.5 Million EUR | -41.72% |
| 2017 Q1 | 4.3 Million EUR | 18.46% |
| 2016 Q3 | 4.02 Million EUR | 23.94% |
| 2016 Q4 | 3.63 Million EUR | -9.72% |
| 2016 FY | - EUR | -13.05% |
| 2016 Q1 | 4.01 Million EUR | 34.81% |
| 2016 Q2 | 3.24 Million EUR | -19.07% |
| 2015 FY | - EUR | 373.71% |
| 2015 Q2 | 3.47 Million EUR | -54.13% |
| 2015 Q3 | 3.12 Million EUR | -10.12% |
| 2015 Q4 | 2.97 Million EUR | -4.74% |
| 2015 Q1 | 7.58 Million EUR | 920.2% |
| 2014 Q1 | 2.66 Million EUR | 361.75% |
| 2014 FY | - EUR | 42.14% |
| 2014 Q4 | 743.14 Thousand EUR | -20.77% |
| 2014 Q3 | 938 Thousand EUR | 277.99% |
| 2014 Q2 | -527 Thousand EUR | -119.8% |
| 2013 Q3 | 885 Thousand EUR | 444.36% |
| 2013 Q4 | -1.01 Million EUR | -214.92% |
| 2013 FY | - EUR | 149.41% |
| 2013 Q1 | 2.93 Million EUR | 16422.22% |
| 2013 Q2 | -257 Thousand EUR | -108.75% |
| 2012 Q1 | 1.81 Million EUR | 386.73% |
| 2012 Q2 | -727 Thousand EUR | -140.06% |
| 2012 Q3 | 852 Thousand EUR | 217.19% |
| 2012 Q4 | -18 Thousand EUR | -102.11% |
| 2012 FY | - EUR | -24.85% |
| 2011 Q1 | 2.12 Million EUR | 0.0% |
| 2011 Q4 | -633 Thousand EUR | 0.0% |
| 2011 FY | - EUR | 619.08% |
| 2011 Q2 | 188 Thousand EUR | -91.14% |
| 2010 Q1 | 1.83 Million EUR | 0.0% |
| 2010 Q2 | 3.61 Million EUR | 96.79% |
| 2010 FY | - EUR | 99.09% |
| 2009 Q1 | 4.71 Million EUR | 0.0% |
| 2009 FY | - EUR | -242.88% |
| 2008 FY | - EUR | 604.28% |
| 2007 FY | - EUR | -75.36% |
| 2006 FY | - EUR | 127.04% |
| 2005 FY | - EUR | -7.82% |
| 2004 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Almirall, S.A. | 122.51 Million EUR | 71.321% |
| Faes Farma, S.A. | 122.93 Million EUR | 71.419% |